Publication at First Faculty of Medicine, Third Faculty of Medicine |
2017
Abstract
The pharmacotherapy of diabetes has been undergoing a very dynamic development during last years. Recently approved drugs confirm the importance of targeted modulation of new systems and, apart from the decrease of glycated hemoglobin, also bring other benefits.
Such a drug is albiglutide, a GLP- 1 agonist with the prolonged action. Its characteristics are briefly discussed in this article.